Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

What is left in pMMR/MSS BRAF V600E metastatic colorectal cancer (mCRC)? Prognostic role of tumor sidedness and molecular co-mutations.

Eleonora Perissinotto, Rossana Intini, Giulia Maddalena et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15608

e15608 Background: BRAF V600E-mutated pMMR/MSS mCRC has poor prognosis. However, real-world outcomes are heterogeneous and...

Neoadjuvant dalpiciclib combined with letrozole and dual HER2 blockade in HR+/HER2+ breast cancer: First-stage results of the HELEN HER2 017 trial.

Jiujun Zhu, Zhenduo Lu, Junzhao Wu et al. Jun 01, 2026 pp. 1054-1054 10.1200/jco.2026.44.16_suppl.1054

1054 Background: Triple-positive breast cancer (TPBC; HR+/HER2+) represents a distinct subtype with suboptimal responses t...

Relationship between immune-mediated adverse events and clinical outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors (ICIs): A retrospective real-world analysis.

Leticia Escobar Vicentini, Mariana Ferrari de Jesus Abdalla, Milton Jose De Barros E Silva et al. Jun 01, 2026 pp. 11144-11144 10.1200/jco.2026.44.16_suppl.11144

11144 Background: ICIs targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated protein 4 (C...

Perceptions of Medicaid coverage and care experiences among long-term survivors of childhood cancer: Qualitative interviews from the Childhood Cancer Survivor study (CCSS).

Xu Ji, Anjali Rachel Khanna, Janet Cummings et al. Jun 01, 2026 pp. 10051-10051 10.1200/jco.2026.44.16_suppl.10051

10051 Background: Childhood cancer survivors require lifelong, risk-based follow-up care. Survivors insured by Medicaid ma...

Colon cancer sidedness in relation to sepsis risk and clinical predictors: A National Inpatient Sample analysis.

Panah Tushar Parab, Edwin Saji, Jason Jacob et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15700

e15700 Background: Colon cancer patients are at increased risk for developing sepsis during hospitalization. It is unclear...

<i>MACROD2</i> and <i>CDKN2A</i> in multiple myeloma: Insights to germline susceptibility and cytogenetic risk from long-read Nanopore sequencing.

Panteha Behboodi, James Di Palma Grisi, Andy Madrid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19566

e19566 Background: The MACROD2 gene is a chromosomal fragile site that undergoes f...

Relative benefit of perioperative chemotherapy after resection for stage III colon cancer in the 70s age range: SEER 2004–2015.

Leeseul Kim Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13778

e13778 Background: The magnitude of survival benefit associated with perioperative chemotherapy after resection for stage...

Real-world patterns and outcomes of cancer-related distress assessed by the NCCN distress thermometer in community oncology practice in western India.

Prakash Devde, Vashista Maniar, Disha Morzaria et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13578

e13578 Background: Cancer-related distress can adversely affect treatment adherence and quality of life, yet real-world ev...

Lipid reprogramming as driver of statin-targetable vulnerability in early-onset prostate cancer.

Qiyu Zhu, Junru Chen, Jinge Zhao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17147

e17147 Background: Early-onset prostate cancer (EOPC, age ≤55 years) is increasing in incidence and displays distinct clin...

Impact of facility type and surgical management on survival outcomes in colon adenocarcinoma stratified by metastatic burden.

Yazmin Reategui-Almonacid, Daniel Moncada, Nkengeh Tazinkeng et al. Jun 01, 2026 pp. 11129-11129 10.1200/jco.2026.44.16_suppl.11129

11129 Background: Survival for colon cancer varies by facility type, yet the impact of granular metastatic burden and surg...

c-MET expression by IHC and response to cabozantinib in patients with relapsed, refractory germ-cell tumor: A single-arm phase II trial.

Jennifer King, Muhammad Idrees, Tareq Salous et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17015

e17015 Background: Cabozantinib, a multi-targeted tyrosine kinase inhibitor targeting c-MET, VEGFR, and AXL, shows clinica...

Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488).

Harriet M. Kluger, David A. Braun, Ivana Djuretic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2687

TPS2687 Background: In recent years, T-cell enhancement strategies have achieved notable survival benefits in patients wit...

Gender representation in first and senior authorship of phase III solid-tumor trials presented at the ASCO Annual Meeting, 2015-2025.

Sarbajit Mukherjee, Azza Sarfraz, Shree Rath et al. Jun 01, 2026 pp. 9006-9006 10.1200/jco.2026.44.16_suppl.9006

9006 Background: Authorship in clinical trials reflects access to research infrastructure, funding, and academic advanceme...

Clinical utility of PET-CT in the management of colorectal liver metastases.

Dermott McMorrough, Niamh Ryan, Molly Godson Treacy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15547

e15547 Background: Patients with colorectal cancer liver metastases (CRCLM) may be considered for potentially curative liv...

Differential risk of interstitial lung disease with DXd-based versus non-DXd TROP2 antibody-drug conjugates: A systematic review and meta-analysis.

Prahlad Rao Kulkarni, Shankar Biswas, Yashasvi Srivastava et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15037

e15037 Background: TROP2 directed antibody drug conjugates (ADCs) have demonstrated efficacy across multiple solid tumors....

Non–small cell lung cancer and the obesity paradox: A retrospective cohort study using the TriNetX database.

Areeba Nayyer, Chadane Thompson, Jasneet Gill et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20544

e20544 Background: Although obesity is traditionally associated with adverse health outcomes, paradoxical survival benefit...

Phase 1 study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in locally advanced squaous cell carcinoma of the head and neck (LA SCCHN).

Omayra Sanchez, Leslie Anne Worona, Emily Ramos et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18085

e18085 Background: Despite advances in therapy, overall survival for locally advanced squamous cell carcinoma of the head...

Correlation between real-world progression-free survival and time to next treatment and death in advanced ovarian cancer patients receiving non-platinum therapy in second or later lines.

Le Su, Lei Chen, Xinyue Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17578

e17578 Background: Advanced ovarian cancer (aOC) is typically treated with platinum-based first-line therapy, but in secon...

SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study.

Ting Xu, Lin Shen, Jian Li et al. Jun 01, 2026 pp. 3569-3569 10.1200/jco.2026.44.16_suppl.3569

3569 Background: HER2 expression is associated with poor prognosis in mCRC. SHR-A1811 (trastuzumab-rezetecan) is a HER2-di...

Quantitative CT lung fibrosis and immune checkpoint inhibitor–related pneumonitis in NSCLC.

Mitchell Boshkos, Amgad Muneer, Eman Showkatian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20531

e20531 Background: Interstitial lung abnormalities (ILAs) are established risk factors for immune checkpoint inhibitor–rel...

Long-term survival results of perioperative chemoimmunotherapy with DCF and avelumab in locally advanced gastro-esophageal adenocarcinoma.

Thierry Alcindor, James Tankel, Pierre-Olivier Fiset et al. Jun 01, 2026 pp. 4096-4096 10.1200/jco.2026.44.16_suppl.4096

4096 Background: We have shown that avelumab, an anti-PD-L1 antibody, added to perioperative modified DCF chemotherapy (aD...

Hospital designation and survival disparities in young-onset gastrointestinal cancer.

Mrinalini Ramesh, Sawyer Bawek, Anneliese Markus et al. Jun 01, 2026 pp. 1535-1535 10.1200/jco.2026.44.16_suppl.1535

1535 Background: Early-onset gastrointestinal (GI) cancers (&lt;50 years) are increasing in incidence. We examined the imp...

SWIVEL: A randomized phase II trial of switching medications versus guideline-directed interventions for adjuvant aromatase inhibitor side effects in breast cancer patients.

Elaine Patricia Kuhn, Isabella Marchal, Tonya MacLean et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps12171

TPS12171 Background: Approximately half of breast cancer patients do not complete the standard 5-year course of adjuvant h...

Clear cell–type squamous cell carcinoma: An NCDB analysis.

Grace S. Saglimbeni, Noureen Nakshbandi, Suraj Puvvadi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21549

e21549 Background: Clear cell–type squamous cell carcinoma (ccSCC) is a rare, aggressive histologic variant of squamous ce...

Patient characteristics and real-world utilization of darolutamide in advanced prostate cancer among a national cohort of veterans.

Richard Mcshinsky, Zach Burningham, Chunyang Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23426

e23426 Background: Darolutamide (DARO) has demonstrated efficacy and a tolerable safety profile in prostate cancer (PC) cl...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page